# Redx Pharma Plc “Focus, Realism and Results” – Ian Ross, Chairman

- Link: https://www.directorstalkinterviews.com/redx-pharma-plc-focus-realism-results-ian-ross-chairman/412753216
- Published: 2018-06-21T08:51:37+01:00
- Author: Giles Arbor

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[Redx Pharma
Plc** (LON:REDX) new management team is focusing its financial resources (ca.£10m)
on progressing its lead candidates in oncology and fibrotic disease into the clinic.
Although the first patient was treated recently in a Phase I/II proof-of-concept
trial with its porcupine inhibitor RXC004, some on-target adverse events (anticipated
at higher doses) were observed, which caused management to take the prudent decision
to stop patient recruitment and prepare a revised protocol to the MHRA for end 2018.
Meanwhile, Redx is continuing to progress its realistic development strategy with
a period-end cash balance of £10.3m.

**Strategy:** Redx is focused on the discovery and early clinical development of
small molecule therapeutics in oncology and fibrotic disease. It is also focused
on taking assets through proof-of-concept clinical trials and then partnering them
to the drug major(s) for late-stage development and commercialisation.

**Interims:** Redx reported progress on its R&D pipeline which is now focused on
two key high value-added areas of cancer and fibrotic disease. Management has tightened
control on costs with a lower spend in SG&A and R&D, reducing the annual cash burn
by ca.£5m p.a.

**RXC004 trial:** A decision was made to temporarily suspend the Phase I/IIa trial
with RXC004 in light of adverse events in the first patient dosed. Early data suggest
a higher exposure and longer half-life in humans that could not have been predicted.
A lower dose protocol is expected to be submitted in 2H’18.

**New CEO appointed:** As from 1 June, REDX has a new CEO, Lisa Anson, who had been
President of AstraZeneca (AZN) UK since 2012. She will bring a wealth of experience,
having held a variety of senior management roles at AZN in the UK and the US. Lisa
is also President of the ABPI.

**Investment summary**: Redx Pharma Plc new management team is moving forward with
a revised business plan that focuses cash resources on progressing its drug leads
in oncology and fibrotic disease into early clinical development. The temporary ‘
hold’ on the RXC004 clinical trial has extended these cash resources by an estimated
four months. While Novartis is paving the way with Wnt inhibition, Redx is a close
follower, with a potentially best-in-class compound.

Share on:
